UPDATE: Two ASX 200 stocks have plunged over 30%, presenting a compelling opportunity for investors to buy low this New Year. As of December 23, 2025, the S&P/ASX 200 Index has surged nearly 3% in the last week, yet some stocks have not shared in the gains, potentially allowing for strategic investments.
Block (ASX: XYZ), a leader in payment processing, opened the year at approximately $139 per share, but recently closed at just $97.84, marking a staggering 30% decline. Despite this downturn, Block reported an 18% year-on-year profit increase for the September quarter and forecasts a gross profit of US$10.243 billion for 2025, up 15% from the previous year. Analysts are optimistic, with TradingView setting an average 12-month price target of $175.33, indicating a potential upside of 79%.
Meanwhile, Telix Pharmaceuticals Ltd (ASX: TLX) has seen its stock price plummet nearly 50% this year. However, recent positive trial results have sparked renewed interest. Broker Bell Potter has highlighted a strong likelihood that Telix’s targeted therapy, Zircaix, will receive US FDA approval next year, which could significantly boost revenues. Bell Potter has set a price target of $23.00 for Telix, suggesting an upside of over 90%.
Investors are encouraged to take a closer look at these stocks as the New Year approaches. Buying opportunities often arise from market fluctuations, and with the fundamentals of these companies showing strength, they could be poised for recovery.
The Motley Fool’s insights suggest that while the broader market has shown resilience, these specific stocks could represent undervalued investments. As we head into 2026, keep watch for further developments in both Block and Telix, as they may rebound strongly if recent trends continue.
This news could be pivotal for investors looking to make strategic moves as the market shifts. Stay tuned for more updates on these stocks and others as the situation develops.
